InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,347.52
(
1.06%
)
US TECH 100
18,509.60
(
1.84%
)
Dow Jones
38,774.01
(
0.16%
)
Brent Oil
78.37
(
1.63%
)
Bitcoin
71,072.27
(
0.63%
)
Post# of 252064
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: DewDiligence post# 73324

Friday, 01/22/2010 8:51:43 AM

Friday, January 22, 2010 8:51:43 AM

Post# of 252064

Also, Pfizer Inc.'s Selzentry was approved by the FDA in August, bringing another HIV anti-viral to the market. [Selzentry is IMO a niche product.]


Merck's vicriviroc, also a CCR5 antagonist, a class that has little role in HIV treatment, failed in two phase III studies in experienced HIV patients.

http://www.reuters.com/article/idCNN2017965820100120?rpc=44
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up